<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027412</url>
  </required_header>
  <id_info>
    <org_study_id>URO</org_study_id>
    <nct_id>NCT05027412</nct_id>
  </id_info>
  <brief_title>En Bloc TURBT With Collins Loop vs Conventional TURBT</brief_title>
  <acronym>TURBT</acronym>
  <official_title>Transurethral En Bloc Resection With Collins Loop vs Conventional Transurethral Resection for the Treatment of Urothelial Bladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Fuenlabrada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, randomized and single-blind study in patients diagnosed&#xD;
      with primary bladder CV. Patients diagnosed by cystoscopy of a bladder tumor and with&#xD;
      indication for endoscopic surgical treatment, who meet the inclusion criteria, and who sign&#xD;
      the Informed Consent (IC), will be randomized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to assess the quality of the resection, defined as the&#xD;
      presence of detrusor muscle in the resected tissue.&#xD;
&#xD;
      The secondary objetives are:&#xD;
&#xD;
        -  Compare the surgical time, hospital stay, urinary catheterization time and incidence of&#xD;
           complications.&#xD;
&#xD;
        -  Compare tumor recurrence after one year of follow up.&#xD;
&#xD;
        -  Determine the number of re-TURB as a consequence of the absence of muscle layer in the&#xD;
           sample or artifacts (Tx)&#xD;
&#xD;
        -  Establish the incidence of conversions as a consequence of difficulties in the technique&#xD;
           or intraoperative bleeding.&#xD;
&#xD;
        -  Compare the degree of satisfaction of the surgeon&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of detrusor muscle in the resected sample</measure>
    <time_frame>1 year of follow up</time_frame>
    <description>yes/no</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Bladder Neoplasm</condition>
  <condition>Bladder Urothelial Carcinoma</condition>
  <condition>Bladder Cancer Stage</condition>
  <condition>Urothelial Carcinoma Recurrent</condition>
  <arm_group>
    <arm_group_label>En Bloc TURBT with Collins Loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the patient is randomized to the TURB group, it will be carried out with a Collins loop, with bipolar energy.&#xD;
After randomization, demographic data (age, sex, exposure to tobacco, occupational risk), symptoms prior to randomization (micro or macrohematuria, LUTS) and laboratory data (urinary cytology, hemoglobin and serum creatinine) will be collected. Finally, the physical characteristics of the lesion will be noted in the cystoscopy immediately prior to the intervention: size, location (s) and appearance of the tumor. After the intervention, the type of procedure (TURB / TUB), the duration of the procedure from when the resector is inserted until the urinary catheter is placed, and complications according to the Clavien-Dindo scale will be recorded. In your first post-surgical check-up, the days of hospital stay and the time of bladder catheterization will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional TURBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The TURB will be carried out with bipolar current according to the traditional technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>En bloc TURBT Collins Loop</intervention_name>
    <description>En bloc TURBT Collins Loop</description>
    <arm_group_label>En Bloc TURBT with Collins Loop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional TURBT</intervention_name>
    <description>Conventional TURBT</description>
    <arm_group_label>Conventional TURBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old.&#xD;
&#xD;
          -  Polypoid / sessile primary tumor.&#xD;
&#xD;
          -  &lt; 3 tumors&#xD;
&#xD;
          -  Tumor size 10 - 30 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt; 4 tumors&#xD;
&#xD;
          -  Size of the largest tumor &lt;1 cm and&gt; 4 cm.&#xD;
&#xD;
          -  Tumor located in the bladder dome.&#xD;
&#xD;
          -  No visualization of the ureteral meatus.&#xD;
&#xD;
          -  Flat or in situ tumor.&#xD;
&#xD;
          -  Non-urothelial tumors.&#xD;
&#xD;
          -  Clotting disorder or treatment with oral anticoagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>emilio f ripalda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Fuenlabrada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>emilio A ripalda, MD</last_name>
    <phone>+34916006000</phone>
    <phone_ext>6185</phone_ext>
    <email>emilio.ripalda@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Otaola Arca, M.D., Ph.D.</last_name>
      <phone>+56 9 4108 9452</phone>
      <email>hugotaolarca@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hugo Otaola Arca, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Álvarez Ardura, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Álvaro Páez Borda, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario de Fuenlabrada</investigator_affiliation>
    <investigator_full_name>Berta Nasarre</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

